Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Atossa Therapeutics, Inc. has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 6 actions are distributed among 6 distinct examiners, meaning each examiner is currently reviewing exactly one matter. These actions are spread across 4 distinct art units, showing a level of technical diversity within the company's biotechnology filings.
SAWYER, JENNIFER C is the busiest examiner for the portfolio, with 1 pending office action. The distribution of 6 actions across 4 art units indicates that the company's applications are being reviewed by several different specialized groups within the patent office. Because there are 6 distinct examiners but only 4 art units, the company is interacting with multiple examiners in at least some of those units. This requires a prosecution approach that can handle different examiner styles even when the technical subject matter is closely related within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WORSHAM, JESSICA N | 1 | 56.3% | +56.3% |
| VANNI, GEORGE STEVEN | 1 | 67.4% | +24.4% |
| HILL, MYRON G | 1 | 66.2% | +20.6% |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
| GILL, RACHEL B | 1 | 65.6% | +28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029812 | VIRAL VACCINE COMPOSITIONS FOR INOCULATING A SUBJECT AGAINST A CORONAVIRUS, AN INFLUENZA VIRUS, OR BOTH | GILL, RACHEL B | 86d overdue |
| 18568768 | REMOTE DETECTION OF PATHOGENS | VANNI, GEORGE STEVEN | — |
| 18568769 | COMPOSITIONS AND METHODS TO INCREASE CORONAVIRUS IMMUNE RESPONSE | HILL, MYRON G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029812 | VIRAL VACCINE COMPOSITIONS FOR INOCULATING A SUBJECT AGAINST A CORONAVIRUS, AN INFLUENZA VIRUS, OR BOTH | GILL, RACHEL B | 86d overdue |
| 18859140 | HIGH DOSE ENDOXIFEN FORMULATIONS AND METHODS OF USE | WORSHAM, JESSICA N | — |
| 18568768 | REMOTE DETECTION OF PATHOGENS | VANNI, GEORGE STEVEN | — |
| 18568769 | COMPOSITIONS AND METHODS TO INCREASE CORONAVIRUS IMMUNE RESPONSE | HILL, MYRON G | — |
| 18279577 | ENDOXIFEN FOR TREATMENT OF OVARIAN CANCER | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1615 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859140 | HIGH DOSE ENDOXIFEN FORMULATIONS AND METHODS OF USE | WORSHAM, JESSICA N | 1615 | §102DP | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18568768 | REMOTE DETECTION OF PATHOGENS | VANNI, GEORGE STEVEN | — | §101§103§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18568769 | COMPOSITIONS AND METHODS TO INCREASE CORONAVIRUS IMMUNE RESPONSE | HILL, MYRON G | 1671 | §102§103§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18279577 | ENDOXIFEN FOR TREATMENT OF OVARIAN CANCER | LEE, WILLIAM Y | 1623 | §103 | Non-Final OA | — | Pending | Aug 30, 2023 |
| 18029812 | VIRAL VACCINE COMPOSITIONS FOR INOCULATING A SUBJECT AGAINST A CORONAVIRUS, AN INFLUENZA VIRUS, OR BOTH | GILL, RACHEL B | 1671 | §103§112 | Final Rejection | 86d overdue | Pending | Mar 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial